Mirae Asset Global ETFs Holdings
TRVI icon

Mirae Asset Global ETFs Holdings’s Trevi Therapeutics TRVI Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$917K Buy
49,143
+4,290
+10% +$62.4K ﹤0.01% 1678
2026
Q1 		$535K Buy
44,853
+2,790
+7% +$31.2K ﹤0.01% 1859
2025
Q4 		$527K Buy
42,063
+1,438
+4% +$16.6K ﹤0.01% 1865
2025
Q3 		$372K Sell
40,625
-920
-2% -$6.9K ﹤0.01% 2013
2025
Q2 		$227K Sell
41,545
-2,598
-6% -$16.2K ﹤0.01% 2213
2025
Q1 		$278K Buy
44,143
+10,445
+31% +$49.8K ﹤0.01% 2149
2024
Q4 		$139K Buy
33,698
+1,501
+5% +$4.8K ﹤0.01% 2560
2024
Q3 		$108K Buy
32,197
+11,046
+52% +$32.8K ﹤0.01% 2685
2024
Q2 		$63K Buy
+21,151
New +$58.8K ﹤0.01% 2728

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's TRVI Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings increased its Trevi Therapeutics (TRVI) stake by 9.6% in Q2 2026, buying an estimated $62.4K and bringing the position to 49,143 shares worth $917K. The position accounts for ﹤0.01% of the portfolio, ranked #1678.

Mirae Asset Global ETFs Holdings first reported a position in TRVI in Q2 2024 and has held it in 9 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Mirae Asset Global ETFs Holdings held 49,143 shares of Trevi Therapeutics worth $917K as of Q2 2026.
  • Mirae Asset Global ETFs Holdings bought 4,290 Trevi Therapeutics shares in Q2 2026, an estimated $62.4K.
  • Trevi Therapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #1678 holding.
  • Mirae Asset Global ETFs Holdings first reported a position in Trevi Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.